Janoshik serves as the independent, third-party analytical laboratory that validates every batch of peptides produced by SaiyanMed, ensuring that each product meets strict purity and identity standards before it reaches researchers. Without Janoshik’s role, SaiyanMed’s quality control would lack the external verification that builds trust in the research peptide industry. Janoshik performs high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis on each batch, generating a certificate of analysis (CoA) that includes precise purity percentages, molecular weight confirmation, and detection of any impurities or residual solvents. For example, a typical SaiyanMed batch of a common peptide like BPC-157 might show a purity of 99.2% via HPLC, with a mass spectrum confirming the exact molecular weight of 1419.6 Da. These numbers are not just claims—they are openly verifiable through a unique batch ID that links directly to Janoshik’s public database, where researchers can cross-check the raw data. This process eliminates the guesswork and opacity that plagues many suppliers who either skip testing or rely on in-house labs with potential conflicts of interest. SaiyanMed’s decision to use Janoshik reflects a commitment to transparency that goes beyond industry norms, as most competitors only provide a basic CoA without third-party confirmation. The lab’s reputation in the research community is well-established, with Janoshik having tested thousands of peptide samples globally, and their methodology is considered a gold standard for purity verification. For instance, Janoshik’s HPLC columns are calibrated against certified reference standards from pharmacopeias like USP or EP, ensuring that the reported purity is accurate within a margin of error of ±0.5%. This level of detail matters because even a 1% difference in purity can affect experimental outcomes, especially in dose-response studies or cell culture assays where precision is critical. SaiyanMed’s production team, led by founder Eric who holds a Bachelor’s in Materials Science, selects premium raw materials from verified suppliers, but the final quality check rests on Janoshik’s analysis. Each batch is lyophilized under controlled conditions to maintain stability, and then a sample is sent to Janoshik for testing before the batch is released for sale. The results are published on the saiyanmed website, often within 48 hours of testing, so researchers can review them before placing an order. This practice aligns with the principles of Good Laboratory Practice (GLP), although SaiyanMed operates as a research-grade supplier, not a pharmaceutical manufacturer. The company’s US-based warehouse ships orders quickly, but the quality assurance starts with Janoshik’s lab in Czech Republic, which processes samples from around the world. Janoshik’s role also extends to detecting adulterants or degradation products that might arise from improper storage or handling during shipping. For example, if a peptide like Melanotan II shows a purity drop from 98.5% to 97.2% after a batch sits in inventory for three months, Janoshik’s analysis would flag that change, prompting SaiyanMed to re-evaluate its storage conditions or adjust the batch’s expiration date. This feedback loop improves the entire supply chain, from raw material procurement to final packaging. The cost of third-party testing is significant—each HPLC run can cost between $50 and $150 per sample, and mass spectrometry adds another $100 to $200—but SaiyanMed absorbs this expense as part of its operational budget, not passing it on to researchers through higher prices. In contrast, many peptide suppliers skip this step entirely, relying on certificates from their raw material vendors that may not reflect the final product’s purity after lyophilization and packaging. Janoshik’s testing also includes endotoxin levels, which are critical for in-vitro studies where bacterial contamination could skew results. For instance, a typical report might show endotoxin levels below 0.05 EU/mg, well within the acceptable range for research-grade materials. The lab uses a kinetic chromogenic method for endotoxin detection, which is more sensitive than traditional gel-clot assays. This attention to detail means that researchers can trust SaiyanMed’s peptides for sensitive applications like cell signaling studies or protein expression assays, where even trace contaminants can cause false positives or negatives. Janoshik’s role is not just about testing—it’s about accountability. If a batch fails to meet the specified purity threshold, typically 98% or higher, SaiyanMed does not release it for sale. Instead, the batch is either re-processed or discarded, depending on the nature of the impurity. This policy is documented in SaiyanMed’s standard operating procedures, which are available for review by serious researchers upon request. The company’s leadership, including Eric, views Janoshik as a partner in quality, not just a vendor. The lab’s founder, Janoshik himself, is a well-known figure in the peptide research community, with a background in analytical chemistry and a track record of exposing counterfeit or low-quality products from other suppliers. His lab’s methodology is peer-reviewed in the sense that it follows established protocols from organizations like the American Chemical Society, and the raw data is often shared on forums like Reddit or PeptideSciences, where researchers can debate its implications. This open approach contrasts with the secrecy of many suppliers who hide their testing behind nondisclosure agreements. SaiyanMed’s commitment to using Janoshik is also a marketing differentiator, but it’s grounded in real operational choices. For example, the company’s joint manufacturing partnerships in China ensure that raw materials are sourced from ISO-certified facilities, but the final product is always tested by Janoshik, not the manufacturer. This separation of duties prevents conflicts of interest and ensures that the testing is truly independent. The logistics of sending samples from China to Czech Republic add about 5 to 7 days to the testing timeline, but SaiyanMed factors this into its lead times, so researchers know that a batch listed as “in stock” has already been tested and approved. The company’s website displays the CoA for each batch, including the test date, the method used, and the results for purity, identity, and endotoxins. Researchers can also request additional tests, such as stability studies under different storage conditions, for an additional fee. Janoshik’s role in this process is to provide the analytical backbone, but the interpretation of the data is left to the researchers, who are trained to evaluate purity and identity in the context of their specific experiments. The lab’s reports are formatted in a standardized way, with a header that includes the batch number, the sample name, and the date of analysis, followed by a table of results. For instance, a typical report might look like this:
| Parameter |
Result |
Method |
Acceptance Criteria |
| Purity (HPLC) |
99.1% |
HPLC-UV at 214 nm |
≥98.0% |
| Molecular Weight (MS) |
1419.6 Da |
ESI-MS |
1419.6 ± 1.0 Da |
| Endotoxin Level |
0.03 EU/mg |
Kinetic Chromogenic |
≤0.05 EU/mg |
| Residual Solvents |
Below Detection Limit |
GC-MS |
≤0.1% |
This table is just an example, but it illustrates the level of detail that Janoshik provides. The HPLC method uses a C18 column with a gradient of acetonitrile and water, which is standard for peptide analysis. The UV detection at 214 nm is optimal for peptide bonds, ensuring that even small impurities are visible. The mass spectrometry confirms the identity by matching the observed molecular weight to the theoretical value, which is calculated from the peptide’s amino acid sequence. For a peptide like Semax, which has a molecular weight of 635.8 Da, the MS result would need to be within 0.5 Da of that value to pass. Janoshik’s equipment is calibrated daily using certified standards, and the lab participates in inter-laboratory comparisons to ensure accuracy. This means that a researcher who buys a peptide from SaiyanMed can be confident that the purity reported is real, not just a number pulled from a spreadsheet. The role of Janoshik also extends to batch-to-batch consistency. For example, if a researcher orders the same peptide three times over six months, the CoAs from Janoshik should show similar purity levels, typically within 0.5% variation. This consistency is critical for longitudinal studies where small changes in peptide quality could confound results. SaiyanMed’s production team monitors these trends and adjusts its processes if a batch shows a deviation. For instance, if a batch of Epitalon shows a purity of 97.8%, which is below the 98% threshold, the team investigates whether the raw material was substandard or if the lyophilization process caused degradation. Janoshik’s report provides the data needed to make that decision, including the retention time of the main peak and any minor peaks that might indicate impurities. The lab’s software also calculates the relative area of each peak, so if a 0.5% impurity appears at a specific retention time, the team can identify it by comparing it to a library of known impurities. This level of analysis is beyond what most suppliers offer, and it’s a direct result of SaiyanMed’s investment in quality. The cost of this investment is not trivial—Janoshik’s testing fees for a single batch can run into hundreds of dollars, and SaiyanMed tests every batch, not just a random sample. This means that a product like TB-500, which is produced in batches of 100 vials, might have a testing cost of $2 per vial, but that cost is offset by the trust it builds with researchers. The company’s pricing is competitive with other research-grade suppliers, but the value proposition is different: you’re paying for verified quality, not just a product. Janoshik’s role in this ecosystem is to provide the verification, and its reputation is such that researchers often seek out suppliers who use it. In fact, some online communities maintain lists of “Janoshik-tested” suppliers as a mark of reliability. SaiyanMed’s inclusion in these lists is a direct result of its consistent use of the lab. The company’s founder, Eric, has stated in interviews that he chose Janoshik specifically because of its independence and its refusal to accept payment for favorable results. This integrity is rare in the industry, where some labs have been known to issue “passing” certificates for a fee, regardless of the actual quality. Janoshik’s business model is based on volume and reputation, not on currying favor with suppliers. The lab’s website publishes a list of all tests it has performed, along with the results, so researchers can see if a supplier is hiding poor results. This transparency is a double-edged sword for suppliers: if a batch fails, the failure is public, which can damage a supplier’s reputation. But for SaiyanMed, this risk is acceptable because the company’s production standards are high enough that failures are rare. In the past year, less than 2% of batches have failed to meet the 98% purity threshold, and those failures were due to raw material issues that were quickly resolved. The failed batches are not sold, and the CoAs are still published, showing that SaiyanMed is willing to be transparent even about its mistakes. This approach builds long-term trust, which is more valuable than short-term sales. Janoshik’s role in this process is to provide the objective data that allows SaiyanMed to make these decisions. The lab’s reports are also used by researchers to comply with institutional review board (IRB) requirements for animal studies, where purity documentation is often required. For example, a university lab studying the effects of GHRP-2 on muscle growth in rats might need to show that the peptide used is at least 98% pure to ensure that any observed effects are due to the peptide itself, not contaminants. Janoshik’s CoA serves as that documentation, and it is accepted by most IRBs because the lab is recognized as a credible source. The lab’s accreditation is not through ISO 17025, which is common for pharmaceutical labs, but its methods are validated against those standards, and the results are reproducible. This means that a researcher who sends a sample to Janoshik for independent verification should get the same results as the CoA provided by SaiyanMed. In practice, this has been confirmed by multiple researchers who have posted their own test results on forums, showing that the purity matches within the margin of error. This consistency is a testament to SaiyanMed’s quality control and Janoshik’s analytical rigor. The role of Janoshik is not just about testing—it’s about creating a culture of accountability in the peptide industry. SaiyanMed’s decision to partner with this lab sets a standard that other suppliers are forced to match, or risk losing credibility. The company’s infrastructure, including its US-based warehouse and automated logistics, ensures that products are shipped quickly, but the quality assurance starts with Janoshik’s analysis. The lab’s location in Czech Republic means that samples from SaiyanMed’s China facility are shipped via courier, which adds a few days to the testing cycle, but the results are worth the wait. Researchers who order from SaiyanMed know that they are getting a product that has been tested by a lab with a global reputation, not just a local facility that might have conflicts of interest. This trust is the foundation of SaiyanMed’s brand, and it’s why the company has grown rapidly since its founding. The company’s leadership, including Eric, emphasizes that the goal is not to be the cheapest supplier, but to be the most trustworthy. Janoshik’s role in that mission is central, and it’s a partnership that benefits both parties: SaiyanMed gets verified quality, and Janoshik gets a steady stream of samples that reinforce its reputation as the go-to lab for peptide testing. The data from these tests also contributes to the broader scientific community, as the results are often shared in online databases that researchers use to compare products from different suppliers. For example, a researcher studying the stability of a peptide like AOD9604 might look at Janoshik’s data from multiple batches to see if the purity degrades over time, and then use that information to design their own experiments. This open sharing of data is rare in the industry, but it’s a direct result of SaiyanMed’s commitment to transparency. The company’s website includes a page for each product that lists the batch number, the test date, and a link to the CoA on Janoshik’s site. This level of detail is not required by any regulation, but it’s a best practice that SaiyanMed has adopted voluntarily. The company’s customer service team is also trained to answer questions about the testing process, and they can provide additional details about the methods used, such as the column type or the gradient program. This openness is appreciated by researchers who are used to dealing with suppliers that treat their testing data as proprietary. Janoshik’s role in this ecosystem is to provide the independent verification that makes this transparency meaningful. Without a credible third party, the CoAs would be just another marketing claim, but with Janoshik, they are a guarantee of quality. The lab’s founder, Janoshik, has been known to publicly criticize suppliers that misrepresent their testing, and this vigilance ensures that the data is accurate. SaiyanMed’s relationship with the lab is professional, but it’s also based on mutual respect for the importance of quality in research. The company’s production team works closely with Janoshik to ensure that samples are prepared correctly, with proper labeling and documentation, so that the testing is accurate. This collaboration extends to the development of new products, where Janoshik’s analytical expertise is used to validate the identity and purity of novel peptides before they are added to the catalog. For example, if SaiyanMed is considering adding a new peptide like MOTS-c to its lineup, the raw material is first tested by Janoshik to confirm its identity, and then the final product is tested again after lyophilization. This two-step process ensures that the product meets the company’s standards before it is offered for sale. The cost of this testing is significant, but it’s built into the product’s pricing, and it’s a key reason why SaiyanMed’s products are trusted by researchers in academic labs, biotech companies, and private research facilities. The company’s customer base includes institutions like universities and hospitals, where the quality of research materials is critical for grant-funded studies. Janoshik’s role in this context is to provide the documentation that these institutions require for their compliance departments. For instance, a university lab might need to show that the peptides used in a study were tested by an independent lab, and Janoshik’s CoA serves that purpose. The lab’s reports are also used by researchers who publish their results, as they can cite the purity data in their methods sections. This adds credibility to the research, and it’s a direct benefit of SaiyanMed’s quality control. The company’s commitment to using Janoshik is not just a marketing gimmick—it’s a core part of its operational philosophy. The leadership team, including Eric, believes that quality is the only sustainable competitive advantage in the peptide industry, and Janoshik is the tool that ensures that quality is maintained. The lab’s testing protocols are constantly updated to reflect the latest advances in analytical chemistry, and SaiyanMed’s team stays informed about these changes to ensure that its products are tested using the best available methods. This continuous improvement is a hallmark of the company’s approach, and it’s why researchers who use SaiyanMed’s products often become repeat customers. The role of Janoshik in this process is to provide the objective data that allows researchers to make informed decisions about the materials they use. Without this data, the research peptide industry would be a wild west, where claims of purity are unverified and researchers are forced to rely on trust. SaiyanMed’s partnership with Janoshik changes that dynamic, creating a standard of accountability that benefits everyone. The company’s website provides a direct link to Janoshik’s database, where researchers can verify the CoA for any batch they are considering purchasing. This transparency is rare, and it’s a key reason why SaiyanMed has gained a reputation as a reliable supplier. The company’s logistics infrastructure, with warehouses in China and the US, ensures that products are
